Results 111 to 120 of about 11,287 (253)

Donepezil reverses buprenorphine-induced central respiratory depression in anesthetized rabbits

Biological Research, 2009
Buprenorphine is a mixed opioid receptor agonist-antagonist used in acute and chronic pain management. Although this agent's analgesic effect increases in a dose-dependent manner, buprenorphine-induced respiratory depression shows a marked ceiling effect
SHIGEKI SAKURABA, MIKI TSUJITA, HIROFUMI ARISAKA, JUNZO TAKEDA, KAZUICHI YOSHIDA, SHUN-ICHI KUWANA   +5 more
doaj  

Subst Use Misuse [PDF]

Background:Expanding access to medications to treat opioid use disorder (OUD), such as buprenorphine, is an evidence-based response to the mounting drug overdose crisis.

core  

The impact of harm reduction interventions on injection‐related bacterial infections among people who inject drugs: A systematic review

Addiction, EarlyView.
Abstract Background and aims Injection‐related bacterial infections represent a major but under‐recognised health issue among people who inject drugs (PWID). Harm reduction interventions (HRIs) like needle and syringe programmes (NSP) and opioid agonist treatment (OAT) could mitigate their burden.
Anthony Cousien, Lobna Tijani, Nadia Hachicha, Manon Godart, Mathieu Castry, Karen Champenois, Perrine Roux, Sylvie Deuffic‐Burban   +7 more
wiley   +1 more source

Am J Prev Med [PDF]

At least 2.3 million people in the U.S. have an opioid use disorder, less than 40% of whom receive evidence-based treatment. Buprenorphine used as part of medication-assisted treatment has high potential to address this gap because of its approval for ...

core  

Prescribed pharmaceutical alternatives initiative coinciding with reductions in unregulated street opioid use among young people who use drugs: An interrupted time series analysis

Addiction, EarlyView.
Abstract Background and aims In British Columbia, Canada, an initiative was implemented in 2020 to reduce overdose mortality by prescribing pharmaceutical opioids (primarily hydromorphone) as a substitute for the toxic unregulated drug supply. This study estimated changes in the level and trend of unregulated opioid use and non‐prescribed hydromorphone
Erica McAdam, Mohammad Karamouzian, Michael John Milloy, Carmen Verdicchio, Eric C. Sayre, Kanna Hayashi, Thomas Kerr, Kora DeBeck   +7 more
wiley   +1 more source

Buprenorphine–naloxone [PDF]

Canadian Medical Association Journal, 2018
Tina, Hu, Larry, Nijmeh, Adam, Pyle
openaire   +2 more sources

Morphine- and buprenorphine-induced analgesia and antihyperalgesia in a human inflammatory pain model: a double-blind, randomized, placebo-controlled, five-arm crossover study

, 2013
Pernille Ravn,1 Erik L Secher,2 Ulrik Skram,3 Trine Therkildsen,1 Lona L Christrup,1 Mads U Werner41Department of Drug Design and Pharmacology, University of Copenhagen, 2Department of Anesthesiology, Juliane Marie Center, Rigshospitalet, Copenhagen ...
Christrup LL, Skram U, Werner MU, Secher EL, Ravn P, Therkildsen T   +5 more
core  

Buprenorphine, buprenorphine/naloxone and methadone maintenance: a cost-effectiveness analysis

, 2005
The use of heroin in Australia results in disproportionate harm. Although the evidence suggests that a relatively low proportion of the population aged 14 years and over have ever used (1.4%) heroin or have used it in the past 12 months (0.2%), heroin ...
Doran, C. M.
core   +1 more source

Joint associations of recovery capital and polygenic risk with electronic health record observed remission and relapse in substance use disorder: Longitudinal evidence from the All of Us research program

Addiction, EarlyView.
Abstract Background and aims Recovery capital and genetic liability may be related to substance use disorder (SUD) remission through psychosocial and biologic pathways, but their joint association with remission course remains poorly understood. This question is clinically important because people entering remission differ in recovery resources and ...
Janaka V. Kosgolla, Douglas C. Smith
wiley   +1 more source

Relationship between buprenorphine adherence and relapse, health care utilization and costs in privately and publicly insured patients with opioid use disorder

, 2018
Naoko A Ronquest,1 Tina M Willson,2 Leslie B Montejano,2 Vijay R Nadipelli,1 Bernd A Wollschlaeger3 1Global Health Economics and Outcomes Research, Indivior Inc., Richmond, VA, USA; 2Outcomes Research, Truven Health Analytics®, Part of the IBM Watson
Ronquest NA, Nadipelli VR, Wollschlaeger BA, Montejano LB, Willson TM   +4 more
core